MyChesCo on MSN
FDA Approves Johnson & Johnson’s Tremfya Subcutaneous Induction for Ulcerative Colitis
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved a subcutaneous induction regimen of TREMFYA (guselkumab) for the treatment of adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback